Search

Your search keyword '"Nomdedeu, Josep"' showing total 523 results

Search Constraints

Start Over You searched for: Author "Nomdedeu, Josep" Remove constraint Author: "Nomdedeu, Josep"
523 results on '"Nomdedeu, Josep"'

Search Results

4. Predictors of outcomes after internal fixation of periprosthetic femoral hip fractures Subgroup analysis of the peri-implant and peri-prosthetic fractures Spanish registry (PIPPAS)

5. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

7. Engraftment characterization of risk-stratified AML in NSGS mice

9. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

10. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

11. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

14. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

15. P718: EPIGENOME PROFILING REVEALS ABERRANT DNA METHYLATION SIGNATURE IN GATA2 DEFICIENCY

16. P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS

18. Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes

19. Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies

21. Supplementary Data from Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

22. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency

24. Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

25. RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRASK117 (TET2/ASXL1)

26. Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

27. Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center.

28. Determinacions del perfil genètic de les malalties neoplàstiques hematològiques

29. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

30. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high‐hyperdiploid B‐cell acute lymphoblastic leukemia

31. Many signs, one mutation: Early onset of de novo GATA2 deficiency syndrome. A case report

32. Author response for 'Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia'

33. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

34. Engraftment characterization of risk-stratified AML patients in NSGS mice

35. The Notch/Hes1 Pathway Sustains NF-κB Activation through CYLD Repression in T Cell Leukemia

36. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

38. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

40. ALL-154: t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

41. Poster: ALL-154: t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

42. Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

44. Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

47. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

Catalog

Books, media, physical & digital resources